Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial.

Journal of cardiology·2022
Same author

Efficacy of Cardiac Computed Tomography for Obstructive Mechanical Valve Thrombosis Under Venoarterial Extracorporeal Membrane Oxygenation.

JACC. Case reports·2022
Same author

Reduction in blood pressure for people with isolated diastolic hypertension and cardiovascular outcomes.

European journal of preventive cardiology·2022
Same author

Takotsubo Syndrome After Additional Right Ventricular Lead Insertion in a Pacemaker User.

Circulation reports·2022
Same author

Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.

Hypertension research : official journal of the Japanese Society of Hypertension·2022
Same author

Relationship between Cardiac Acoustic Biomarkers and Pulmonary Artery Pressure in Patients with Heart Failure.

Journal of clinical medicine·2022
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Related Experiment Video

Updated: May 23, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

[Basic efficiently of drug eluting stent 2011]

Yutaka Hikichi1, Koichi Node

  • 1Cardiovascular Division, Saga University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|April 24, 2012
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention
11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

Related Experiment Videos

Last Updated: May 23, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention
11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016